Related Experiment Video

Updated: Jul 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies

Junfeng Guo1,2, Qiuyuan Wen1,2, Songqing Fan1,2

  • 1Department of Pathology The Second Xiangya Hospital Central South University Changsha China.

Medcomm
|July 6, 2026
PubMed

Insights

Resistance to osimertinib in non-small cell lung cancer (NSCLC) is often driven by SMARCA4 loss, which impacts the tumor microenvironment and signaling pathways. Understanding these mechanisms is crucial for developing new treatments for EGFR-mutated NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) with EGFR mutations is a significant global health concern.
  • Osimertinib, an EGFR-TKI, has improved outcomes but acquired resistance limits its long-term use.

Purpose of the Study:

  • To review key mechanisms of osimertinib resistance in EGFR-mutated NSCLC.
  • To highlight the role of SMARCA4 in mediating resistance.
  • To discuss emerging therapies for overcoming osimertinib resistance.

Main Methods:

  • Literature review of osimertinib resistance mechanisms.
  • Focus on EGFR-dependent and independent pathways.
  • Analysis of SMARCA4's role in chromatin remodeling and signaling.

Main Results:

  • SMARCA4 loss confers osimertinib resistance by modulating the tumor microenvironment via NRF2 and PI3K/AKT pathways.
  • EGFR-independent resistance mechanisms, including bypass pathway activation, are significant.
  • Novel targeted agents and combination therapies show promise against resistance.

Conclusions:

  • SMARCA4 plays a critical role in osimertinib resistance through epigenetic and signaling alterations.
  • Addressing resistance requires a comprehensive understanding of diverse resistance mechanisms.
  • Further research into novel therapies is essential for improving precision treatment in EGFR-mutant NSCLC.
Keywords:
Osimertinib resistanceSWI/SNF relatedactin dependent regulator of chromatinepidermal growth factor receptor mutation (EGFR)matrix associatedmember 4 (SMARCA4)non–small cell lung cancersubfamily Atherapeutic strategy

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...